Claims
- 1. A glucocorticoid of general formula I
- R--Val--O--GC (I),
- in which
- O-GC is the radical of a 21-hydroxycorticoid that has an antiinflammatory action,
- Val represents a valine radical in the 21-position of the corticoid and
- R means a hydrogen atom or a hydrocarbon radical with up to 32 carbon atoms that is optionally substituted by hydroxy groups, amino groups, oxo groups and/or halogen atoms and/or interrupted by oxygen atoms, SO.sub.2 groups and/or NH groups a salt thereof.
- 2. A pharmaceutical preparation comprising a glucocorticoid according to claim 1 and a pharmaceutically acceptable carrier.
- 3. A glucocorticoid of general formula II ##STR2## in which R.sup.1 =H, CH=O, (C=O)R", (C=O)OR" or SO.sub.2 R"
- X.sup.1 -X.sup.3 =independently of one another, alanine, proline or valine,
- A-B=CH.sub.2 --CH.sub.2 or CH=CH
- R.sup.6 =H, F, Cl, Me,
- R.sup.9 =H, F, Cl,
- R.sup.16 =H, Me, OH,
- R.sup.17 =H, OH, O(C=O)R'" or
- R.sup.16, R.sup.17 =alkylidenedioxy, in which
- R" represents a hydrocarbon radical that contains C.sub.1 -C.sub.18 and
- R'" represents a straight-chain a branched-chain C.sub.1 -C.sub.10 alkyl, aryl, alkylaryl or C.sub.1 -C.sub.3 alkoxy radical and
- the alkylidene radical is derived from an aliphatic aldehyde that contains 1-6 carbon atoms, a ketone that contains 3-6 carbon atoms or cyclic ketone or benzaldehyde that contains 5-6 carbon atoms or a salt therof.
- 4. A pharmaceutical preparation comprising a glucocorticoid according to claim 3 and a pharmaceutically acceptable carrier.
- 5. A glucocorticoid of general formula I
- R--Val--O--GC (I),
- in which O--GC is the radical of a 21-hydroxycorticoid that has an antiinflammatory action,
- Val represents a valine radical in the 21-position of the corticoid and
- R means a hydrogen atom or a hydrocarbon radical with up to 32 carbon atoms that is optionally substituted by hydroxy groups, amino groups, oxo groups and/or halogen atoms and/or interrupted by oxygen atoms, SO.sub.2 groups and/or NH groups; or general formula II ##STR3## in which R.sup.1 =H, CH=O, (C=O)R" or SO.sub.2 R",
- X.sup.1 and X.sup.2 =alanine,
- X.sup.3 =proline or valine,
- A--B=CH.sub.2 --CH.sub.2 or CH=CH,
- R.sup.6 =H, F, Cl, Me,
- R.sup.9 =H, F, Cl,
- R.sup.16 =H, Me, OH,
- R.sup.17 =H, OH, O(C=O)R'" or
- R.sup.16, R.sup.17 =alkylidenedioxy, in which
- R" represents a hydrocarbon radical that contains C.sub.1 -C.sub.18 and
- R'" represents a straight-chain or branched-chain C.sub.1 -C.sub.10 alkyl, aryl, alkylaryl or C.sub.1 -C.sub.3 alkoxy radical and
- the alkylidene radical is derived from an aliphatic aldehyde that contains 1-6 carbon atoms, a ketone that contains 3-6 carbon atoms or cyclic ketone or benzaldehyde that contains 5-6 carbon atoms or a salt thereof.
- 6. A method for treating inflammatory conditions, wherein a glucocorticoid according to claim 5 is administered to a patient in need thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
43 11 987.5 |
Apr 1993 |
DEX |
|
Parent Case Info
This application is a 371 of PCT/EP94/00937 filed Mar. 24, 1994.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP94/00937 |
3/24/1994 |
|
|
10/6/1995 |
10/6/1995 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO94/22898 |
10/13/1994 |
|
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
9310141 |
May 1993 |
WOX |